Prevage Antioxidant Cream
Allergan launches Prevage TM
IRVINE, Calif.--Jan. 4, 2005--Allergan, Inc. (NYSE:AGN) today announced the launch of PREVAGE(TM) antioxidant cream, the first and only clinically tested antioxidant that not only reduces the appearance of fine lines and wrinkles, but also provides protection against environmental factors including sun damage, air pollution and cigarette smoke.(1)
Representing the next generation of antioxidants, PREVAGE(TM) antioxidant cream is a novel cosmeceutical containing 1 percent idebenone - a revolutionary, potent and effective new antioxidant.
"We had sun block in the seventies and glycolic acids in the eighties, and now we have PREVAGE(TM) antioxidant cream, the first advance we have seen in decades that is backed by scientific studies," said Jeanine B. Downie, M.D., Director of Image Dermatology, Montclair, New Jersey. "PREVAGE(TM) antioxidant cream is a potent antioxidant that is clinically proven to not only protect the skin against sun damage and the environment, but also to correct fine lines and wrinkles."
Proven Scientific Evidence
Data that compare leading antioxidants show that idebenone is the most effective topical antioxidant product available.(1) A six-week clinical study evaluated the use of PREVAGE(TM) antioxidant cream containing a 1 percent concentration of idebenone in 21 women between the ages of 18 and 65 with moderate photoaging (dry facial skin and fine lines/wrinkles). The women in the study applied PREVAGE(TM) antioxidant cream twice a day to the facial area for six weeks. Study results included:
-- 29 percent reduction in the appearance of fine lines and wrinkles;
-- 26 percent reduction in skin roughness or dryness;
-- 37 percent increase in skin hydration; and,
-- 33 percent overall global improvement in the appearance of skin.(2)
"While other creams just sit on the skin's surface, the unique formulation of PREVAGE(TM) antioxidant cream allows it to penetrate the skin at the cellular level to help prevent free radicals from breaking down the collagen and elastin in the skin," added Dr. Downie.
"PREVAGE(TM) antioxidant cream is the newest addition to our dermatology franchise," said Bob Rhatigan, Vice President, Allergan's U.S. Dermatology business unit. "With a rich heritage in skincare, we are excited to continue providing dermatologists and plastic surgeons with products supported by science and proven results."
PREVAGE(TM) antioxidant cream is available exclusively through dermatologists' and plastic surgeons' offices. To locate an office or for more information, please visit:
www.prevage.com
About Idebenone
When compared to other commonly known topical antioxidants available in skincare products, idebenone is the most potent and effective antioxidant compound. Idebenone has been found to be effective in protecting the skin against key environmental stressors known to cause fine lines and wrinkles including: ultraviolet radiation, ozone, air pollution and cigarette smoke. It also was ranked the most effective compound tested in a series of biochemical and cell-biological methods used to determine the effectiveness of antioxidant compounds at preventing biological damage as a result of oxidative stress.(1)
A close relative of the compound Co-Enzyme Q10, idebenone has far greater skin penetration potential and a much higher oxidative stress protection capacity.(1) Its lower molecular weight allows for greater skin penetration and extended shelf life stability.
About Allergan, Inc.
Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator, skin care and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives.
Forward-Looking Statements
This press release contains "forward-looking statements," including the statements by Dr. Downie and other statements regarding the effectiveness of PREVAGE(TM) antioxidant cream. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and pharmaceutical market conditions; general domestic and international economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new pharmaceutical and biologic products and/or the acceptance of new indications for such products; potential difficulties in manufacturing a new product formulation; domestic and foreign health care reforms; trends toward managed care and health care cost containment; and governmental laws and regulations affecting domestic and foreign operations. Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting Allergan and its Businesses" in Allergan's 2003 Form 10-K and Allergan's Form 10-Q for the quarter ended March 26, 2004. Copies of Allergan's press releases and additional information about Allergan is available on the World Wide Web at:
www.allergan.com
or you can contact the Allergan Investor Relations Department by calling 1-714-246-4636.
(1) 2004 AAD Poster Exhibit: Antioxidants Compared in a New Protocol to Measure Protective Capacity Against Oxidative Stress - Part II; DiNardo, J., Lewis, J., Neudecker, B., Dimitar, B., Wieland, E., Maibach, H.
(2) Six Week Clinical Evaluation of PREVAGE(TM) for the Treatment of Photoaging; DiNardo, J.
Contacts:
Allergan, Inc., Irvine
Jim Hindman (Investors), 714-246-4636
Joann Bradley (Investors), 714-246-4766
Ashwin Agarwal (Investors), 714-246-4582
Stephanie Fagan (Media), 714-246-5232
(press release from Allergan, Inc.)
Untitled Page
|
Med Spa & Laser
